
|Articles|July 18, 2019
Management of ocular inflammation and pain using novel insert
Author(s)Julianne Mobilian
ICMYI: Dr. Tyson shares his pearls using the dexamethasone 0.4 mg insert (Dextenza, Ocular Therapeutix).
Advertisement
Sydney Tyson, MD, shares the take-home message from the presentation he delivered at the 2019
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
ONL Therapeutics reports positive phase 1b data for xelafaslatide in geographic atrophy
2
FDA feedback supports Azura’s Ophthalmic's planned NDA for AZR-MD-001 in MGD
3
Alcon raises offer in amended deal to acquire STAAR Surgical
4
Improved grading scales for oncology drugs causing ocular adverse events
5













































.png)


